Absence of post-treatment changes in sentinel lymph nodes does not translate into increased regional recurrence rate in initially node-positive breast cancer patients.
Breast cancer
Neoadjuvant
Post-treatment changes
Regional recurrence
Sentinel lymph node biopsy
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
26
05
2023
accepted:
10
08
2023
medline:
11
10
2023
pubmed:
8
9
2023
entrez:
7
9
2023
Statut:
ppublish
Résumé
To determine whether the absence of post-treatment changes in the negative sentinel lymph nodes (SLN) in the neoadjuvant setting for biopsy-proven cN + disease results in an increased regional recurrence (RR) rate in patients after SLN biopsy (SLNB) only. Breast cancer patients with biopsy-proven cN + disease who converted to node-negative disease after neoadjuvant systemic treatment (NAST) and underwent SLNB only were included. Retrospective analysis was performed for patients diagnosed between 2008 and 2021. Pathohistological specimens were reviewed for the presence of post-treatment changes in the SLNs. Patients with negative SLNs (ypN0) were divided into two groups: (i) with post-treatment changes, (ii) without post-treatment changes. Patients' characteristics were compared between groups. Crude RR rates were compared using the log-rank test. Recurrence-free (RFS) and overall survival (OS) for the entire cohort were calculated using Kaplan-Meier. Of 437 patients with cN + disease, 95 underwent SLNB only. 82 were ypN0, 57 with post-treatment changes (group 1), 25 without post-treatment changes (group 2). During the median follow-up of 37 months (range 6-148), 1 isolated regional recurrence occurred in group 2 (RR rate 0% for group 1 vs. 4% for group 2, p = 0.149). There were no differences in 3-year RFS and OS between groups. Absent post-treatment changes in negative SLNs for biopsy-proven cN + disease that covert to node-negative after NAST did not result in increased regional recurrence rates in our cohort. Multidisciplinary input is essential to determine whether additional treatment is needed in these patients.
Identifiants
pubmed: 37679645
doi: 10.1007/s10549-023-07084-x
pii: 10.1007/s10549-023-07084-x
pmc: PMC10564834
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
443-450Informations de copyright
© 2023. The Author(s).
Références
JAMA. 2017 Sep 12;318(10):918-926
pubmed: 28898379
Ann Surg Oncol. 2018 Sep;25(9):2596-2602
pubmed: 29978369
Ann Surg Oncol. 2016 Oct;23(11):3467-3474
pubmed: 27160528
Eur J Surg Oncol. 2021 Apr;47(4):804-812
pubmed: 33092968
Ann Surg Oncol. 2003 Aug;10(7):734-9
pubmed: 12900363
JAMA Oncol. 2021 Dec 01;7(12):1851-1855
pubmed: 34617979
Ann Surg. 2016 Apr;263(4):802-7
pubmed: 26649589
Ann Surg Oncol. 2016 Oct;23(11):3475-3480
pubmed: 27469123
Breast. 2021 Oct;59:256-269
pubmed: 34325383
Breast J. 2023 Jan 4;2023:4549033
pubmed: 36694670
Surgeon. 2021 Feb;19(1):1-7
pubmed: 32192932
Clin Exp Metastasis. 2018 Aug;35(5-6):443-454
pubmed: 29796854
Eur J Surg Oncol. 2016 Mar;42(3):361-8
pubmed: 26746091
J Clin Oncol. 2015 Jan 20;33(3):258-64
pubmed: 25452445
Eur Radiol. 2005 May;15(5):1044-50
pubmed: 15856254
Cancer. 2010 Jun 15;116(12):2878-83
pubmed: 20564394
Ann Surg Oncol. 2021 May;28(5):2621-2629
pubmed: 33095362
Clin Breast Cancer. 2022 Jun;22(4):e597-e603
pubmed: 35086763
Ann Surg Oncol. 2020 Nov;27(12):4795-4801
pubmed: 32779055
Ann Surg Oncol. 2019 Dec;26(13):4381-4389
pubmed: 31605339
Lancet Oncol. 2013 Jun;14(7):609-18
pubmed: 23683750
Breast Cancer Res Treat. 2017 May;163(1):159-166
pubmed: 28213782
JAMA. 2013 Oct 9;310(14):1455-61
pubmed: 24101169
Ann Surg Oncol. 2019 Oct;26(11):3502-3509
pubmed: 31228134